DOI QR코드

DOI QR Code

Association between Genetic Polymorphism of Peroxisome Proliferator-Activated Receptor Alpha Leu162Val and Metabolioc Syndrome in Korean

한국인에서 peroxisome proliferator-activated receptor alpha Leu162Val 유전자 다형성과 대사증후군간의 관련성

  • Shin Soung-Cheal (Department of Preventive Medicine, College of Medicine, Kosin University) ;
  • Song Hye-Soon (Department of Preventive Medicine, College of Medicine, Kosin University) ;
  • Hong Young-Seoub (Department of Preventive Medicine, College of Medicine, Dong-A University) ;
  • Kwak Jong-Young (Medical Research Center for Cancer Molecular Therapy, Department of Biochemistry, College of Medicine, Dong-A University) ;
  • Yoo Byung-Chul (Department of Preventive Medicine, College of Medicine, Kosin University) ;
  • Lee Yong-Hwan (Department of Preventive Medicine, College of Medicine, Kosin University)
  • 신승철 (고신대학교 의과대학 예방의학교실) ;
  • 송혜순 (고신대학교 의과대학 예방의학교실) ;
  • 홍영습 (동아대학교 의과대학 예방의학교실) ;
  • 곽종영 (동아대학교 암분자치료연구센타) ;
  • 유병철 (고신대학교 의과대학 예방의학교실) ;
  • 이용환 (고신대학교 의과대학 예방의학교실)
  • Published : 2006.04.01

Abstract

Peroxisome proliferator activated receptor (PPAR)-$\alpha$ of three PPAR subtypes ($-\alpha,\;-\beta/-\gamma,\;-\delta$), which are members of the nuclear hormone receptor superfamily of ligand-activated transcription factors, plays a key role in lipoprotein and glucose homeostasis. A variation in the PPAR-a gene expression has been suggested to influence the development of metabolic syndrome through alterations in lipid concentrations. The aim of our study was to investigate the association between the PPAR-a and metabolic syndrome among South Korean. A total of 542 health screen examinees were enrolled in this study who were examined in Kosin University Gospel Hospital from December, 2004 to July, 2005. The height, weight, waist circumference, and systolic and diastolic blood pressure of the subjects were examined and fasting blood glucose, total cholesterol, HDL cholesterol, LDL cholesterol, triglyceride were measured by-sampling in venous blood. The metabolic syndrome was defined as the presence of three or more of the following : waist circumference men ${\geq}90cm$, women ${\geq}80cm$, blood pressure ${\geq}130/85mmHg$, fasting glucose ${\geq}110mg/dL$, HDL cholesterol men <40 mg/dL, women <50 mg/dL, triglyceride ${\geq}150mg/dL$. The blood pressure, fasting glucose, HDL cholesterol, triglyceride were evaluated by using the criteria of NECP ATP III and waist circumference was assessed by using the criteria of WHO Asia-Western Pacific. And the author compared the frequency of the PPAR-$\alpha$ mutation of L162V ($C{\rightarrow}G$ variant in exon 5) in a sample of 542 subjects with and without the metabolic syndrome by polymerase chain reaction allele-specific oligonucleotide (PCR-ASO) method. One (0.2%) hetero-isotype among high risk of metabolic syndrome was identified. The values of waist circumference, body mass index and low density lipoprotein cholesterol of the mutant were 100 cm, 28.6 $kg/m^2$ and 120 mg/dL, respectively. Although the author failed to see significant association between the presence of the PPAR-$\alpha$ L162V polymorphism and metabolic syndrome, one PPAR-$\alpha$ L162V polymorphism in metabolic syndrome patients was found.

Peroxisome proliferator-activated receptors alpha (PPAR $\alpha$)는 지질대사와 관련하여 대사증후군 발생과 관련이 있을 수 있는 강력한 잠재 유전자로 고려되고 있으므로 한국인에 있어서 PPAR$\alpha$ L162V 유전자 다형성과 대사증후군과의 연관성을 확인하고자 고신대학교 복음병원에서 2004년 12윌에서 2005년 7월 사이에 건강진단을 받았던 수진자 542명(대사 증후군 : 262명, 정상인 : 280명)을 대상으로 신장, 체증, 체질량지수, 허리둘레와 수축기와 이완기 혈압, 공복 혈당, 총콜레스테롤, HDL 콜레스테롤, LDL 콜레스테롤과 중성지방 수치를 측정하였으며, 대사증후군의 정의는 혈압, 공복 혈당, HDL 콜레스테롤, 중성지방은 NCEP ATP III의 기준을 적용하였고, 허리둘레는 WHO 아시아-서태평양 기준을 적용하였다. PCR-ASO (polymerase chain reaction allele-specific oligonucleotide) 방법에 의해 대상자들의 PPAR$\alpha$ L162V 유전자 다형성을 확인하였다. 연구결과 PPAR$\alpha$ 484번 염기서열의 $C{\rightarrow}G$ 돌연변이가 나타난 사람은 조사대상자 542명 가운데 1명(0.2%) 이었다. 한국인에서는 PPAR$\alpha$ L162V 유전자 다형성이 거의 일어나지 않았으며, 이의 확인을 위하여 더욱 많은 사람을 대상으로 연구가 진행되어야 할 필요가 있을 것으로 생각된다.

Keywords

References

  1. Auboeuf, D., J. Rieusset, L. Fajas, P. Vallier, V. Frering, J. P Riou, B. Staels, J. Auwerx, M. Laville and H. Vidal. 1997. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes 46, 1319-1327 https://doi.org/10.2337/diabetes.46.8.1319
  2. Bouchard, C. 1995. Genetics and the metabolic syndrome. Int. J. Obes. 19(Suppl. 1), S52-S59
  3. Chinetti, G., F. G. Gbaguidi, S. Griglio, Z. Mallat, M. Antonucci, P. Poulain, J. Chapman, J. C. Fruchart, A. Tedgui, J. Najib-Fruchart and B. Staels. 2000. CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator- activated receptors. Circulation 101, 2411-2417 https://doi.org/10.1161/01.CIR.101.20.2411
  4. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection. 2001. Evaluation and treament of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285, 2486-2497 https://doi.org/10.1001/jama.285.19.2486
  5. Flavell, D. M., T. I. Pineda, Y. Jamshidi, D. Evans, J. R. Diamond, R. S. Elkele, S. R. Bujac, G. Miller, P. J. Talmud, B. Stales and S. E. Humphries. 2000. Variation in the PPAR alpha gene is associated with altered function in vitro and plasma lipid concentrations in Type II diabetic subjects. Diabetologica 43, 673-680 https://doi.org/10.1007/s001250051357
  6. Garenc, C., S. Aubert, J. Laroche, J. Girouard, M. C Vohl, J. Bergeron, F. Rousseau and P. Julien. 2004. Population prevalence of APOE, APOC3 and PPAR-$\alpha$ mutations associated to hypertriglyceridemia in French Canadians. J. Hum. Genet. 49, 691-700 https://doi.org/10.1007/s10038-004-0208-6
  7. Gouni-Berthold, I., E. Giannakidou, D. Muller-Wieland, M. Faust, J. Kotzka, H. K. Berthold and W. Krone. 2004. Association between the PPAR$\alpha$ L162V polymorphism, plasma lipoprotein levels, and atherosclerotic disease in patients with diabetes mellitus type 2 and in nondiabetic controls. Am. Heart. J. 147, 1117-1124 https://doi.org/10.1016/j.ahj.2003.12.005
  8. Grundy, S. M., B. Hansen, S. C. Jr. Smith, J. I. Cleeman and R. A. Kahn. 2004. Clinical management of metabolic syndrome: report of the American heart association/national heart, lung, and blood institute/American diabetes Association conference on scientific issues related to management. Circulation 109, 551-556 https://doi.org/10.1161/01.CIR.0000112379.88385.67
  9. Grundy, S. M. 1999. Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. Am. J. Cardiol. 83, 25F-29F https://doi.org/10.1016/S0002-9149(99)00211-8
  10. Haffner, S. M., R. A. Valdez, H. P. Hazuda, B. D. Mitchell, P. A. Morales and M. P. Stern. 1992. Prospective analysis of the insulin resistance syndrome (syndrome X). Diabetes 41, 715-722 https://doi.org/10.2337/diabetes.41.6.715
  11. Isseman, I and S. Green. 1990. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347, 645-650 https://doi.org/10.1038/347645a0
  12. Krey, G., O. Braissant, F. L Horset, E. Kalkhoven, M. Perroud, M. G. Parker and W. Wahli. 1997. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator- dependent receptor ligand assay. Mol. Endocrinol. 11, 779-791 https://doi.org/10.1210/me.11.6.779
  13. Kris-Etherton, P., S. R. Daniels, R. H. Eckel, M. Engler, B. V. Howard, R. M. Krauss, A. H. Lichtenstein, F. Sacks, S. St. Jeor, M. Stampfer, S. M. Grundy, L. J. Appel, T. Byers, H. Campos, G. Cooney, M. A. Denke, E. Kennedy, P. Marckmaaa, T. A. Pearson, G. Riccardi, L. L. Rudel, M. Rudrum, D. T. Stein, R. P. Tracy, V. Ursin, R. A. Vogel, P. L. Zock, T. L. Bazzarre and J. Clark. 2001. AHA scientific statement: summary of the scientific conference on dietary fatty acids and cardiovascular health. Conference summary from the nutrition committee of the American heart association. J. Nutr. 131, 1322-1326
  14. Lacquemant, C., F. Lepretre, T. I. Pineda, M. Manraj, G. Charpentie, J. Ruiz, B. Stales and P. Froguel. 2000. Mutation screening of the $PPAR{\alpha}$ gene in type 2 diabetes associated with coronary heart disease. Diabetes Metab. 26, 393-401
  15. Lehmann, J. M., J. M Lenhard, B. B. Oliver, G. M. Ringold and S. A. Kliewer. 1997. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J. Biol. Chem. 272, 3406-3410 https://doi.org/10.1074/jbc.272.6.3406
  16. Mascaro, C., E. Acosta, J. A. Oritz, P. F. Marrero, F. G. Hegardt and D. Haro. 1998. Control of human muscle- type carnitine palmitoyltransferase I gene transcription by peroxisome proliferator activated receptor. J. Biol. Chem. 273, 8560-8563 https://doi.org/10.1074/jbc.273.15.8560
  17. Osumi, T., J. K. Wen and T. Hashimoto. 1991. Two cis-act ing regulatory sequences in the peroxisome proliferator- responsive enhancer region of rat acyl-CoA oxidase gene. Biochem. Biophys. Res. Commun. 175, 866-871 https://doi.org/10.1016/0006-291X(91)91645-S
  18. Park, H. S., S. W. Oh, J. H. Kang, Y. W. Park, J. M. Choi, Y. S. Kim, W. H. Choi, H. J. Yoo and Y. S. Kim. 2003. Prevalence and associated factors with metabolic syndrome in South Korea -From the Korean National Health and Nutrition Examination Survey, 1998-. J. Korean Soc. Study Obes. 12, 1-13
  19. Park, Y. W., S. Zhu, L. Palaniappan, S. Heshka, M. R. Camethon, S. B. Heymsfield. 2003. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the third National Health and Nutritional Examination Survey, 1988-1994. Arch. Intern. Med. 163, 427-436 https://doi.org/10.1001/archinte.163.4.427
  20. Reaven, G. M .1998 Role of insulin resistance in human disease. Diabetes 37, 1595-1607 https://doi.org/10.2337/diabetes.37.12.1595
  21. Robitaille, J., C. Brouillette, A. Houde, S. Lemieux, L. Perusse, A Tchernof, D. Gaudet and M. C. Vohl. 2004. Association between the $PPAR-{\alpha}$ L162V polymorphism and components of the metabolic syndrome. J. Hum. Genet. 49, 482-89
  22. Schoonjans, K., G. Martin, B. Staels and J. Auwerx. 1997. Peroxisome proliferator-activated receptors, orphans with ligands and functions. Curr. Opin. Lipidol. 8, 159-166 https://doi.org/10.1097/00041433-199706000-00006
  23. Schoonjans, K., B. Staels and J Auwerx. 1996. The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. Biochim. Biophys. Acta. 1302, 93-109 https://doi.org/10.1016/0005-2760(96)00066-5
  24. Schoonjans, K., B. Staels and J. Auwerx. 1996. Role of the peroxisome proliferator activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J. Lipid. Res. 37, 907-925
  25. Stales, B., J. Dallongeville, J. Auwerx, K. Schoonjans, E. Leitersdorf and J. C. Fruchart. 1998. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 98, 2088-2093 https://doi.org/10.1161/01.CIR.98.19.2088
  26. Tai, E. S., S. Demissie, L. A. Cupples, D. Corella, P. W. Wilson, E. J. Schaefer and J. M. Ordovas. 2002. Association between the PPARA L162V polymorphism and plasma lipid levels: the Framingham offspring study. Arterioscler. Thromb. Vasc. Biol. 22, 805-810 https://doi.org/10.1161/01.ATV.0000012302.11991.42
  27. Vohl, M. C., P. Lepage, D. Gaudet, C. Brewer, C. Betard, P. Perron, G. Houde, C. Cellier, J. M. Faith, J. P. Despres, K. Morgan and T. J. Hudson. 2000. Molecular scanning of the human $PPAR{\alpha}$ gene: association of the L162V mutation with hyperapobetalipoproteinemia. J. Lipid. Res. 41, 945-52
  28. Western Pacific Regional Office of the World Health Organization. 2000. The International Obesity Task Force: The Asia-Pacific Perspective: redefining obesity and its treatment. Sydney: Health Communications, Australia, http//www.obesityasiapacific.com